That is none other than weight loss drug Zepbound ... EBITDA for the company grew from $3.95 billion to $5.02 billion. In the chart above, you can see financial results for the first nine months ...

In December, Zepbound outperformed rival Novo Nordisk’s NVO Wegovy (semaglutide) in a weight-loss head-to-head study ... an oral GLP-1 small molecule and retatrutide, a GGG tri-agonist and ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

An experimental weight loss drug, retatrutide, has demonstrated encouraging results in helping obese adults lose weight. Randomized controlled trials (RCTs) assessed the efficacy and safety of ...

compared to a 22.5% weight loss achieved by Lilly’s obesity treatment Zepbound over 72 weeks. The latest trial results of Lilly’s next-generation drug, retatrutide, demonstrated an average ...

Those who received GLP-1s experienced decreased absolute and relative weight loss vs. placebo across 26 randomized studies. Retatrutide conferred the greatest weight reduction among all GLP-1s.

But they also highlighted the potential superiority of newer compounds currently under development such as retatrutide, which has helped people lose more than 20% of their original body weight in ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...